TNDM

Business

Tandem Diabetes Care: A Value Play After Steep Decline, or Value Trap?

Shares of insulin pump maker Tandem Diabetes Care have plummeted over 80% in five years, trading near $20. A deep dive into valuation metrics suggests the stock may now be modestly undervalued, but significant risks and competitive pressures remain.

Business

Three Sub-$50 Stocks Facing Headwinds: Why Investors Should Proceed with Caution

While stocks priced between $10 and $50 often signal companies past their initial hurdles, some still grapple with unproven models and market volatility. We examine three such stocks where the risk may outweigh the potential reward.